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Abstract: Glioblastoma multiforme (GBM) is the most aggressive malignant tumor of the central
nervous system, with poor survival in both treated and untreated patients. Recent studies began to
explain the molecular pathway, comprising the dynamic structural and mechanical changes involved
in GBM. In this context, some studies showed that the human glioblastoma cells release high levels of
glutamate, which regulates the proliferation and survival of neuronal progenitor cells. Considering
that cancer cells possess properties in common with neural progenitor cells, it is likely that the
functions of glutamate receptors may affect the growth of cancer cells and, therefore, open the road to
new and more targeted therapies.
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1. Glioblastoma
Gliomas are the most frequent type of primary tumors of the central nervous system in adults.
Among them, glioblastoma multiforme (GBM) is the most malignant brain tumor in adults, with
complex biology and poor prognosis. Typically, primary GBMs, the most frequent type of glioblastomas,
develop de novo without pre-cancerous lesions, whereas the secondary GBMs progress from low-grade
or anaplastic astrocytomas. From the histological point of view, primary and secondary glioblastomas
are quite similar, but they differ from a genetic point of view. Indeed, secondary GBMs carry the IDH1
mutations associated with hypermethylation of the phenotype which are absent in primary GBMs.
Moreover, primary GBMs generally show EGF gene amplification, together with the phosphatase/tensin
homolog (PTEN) mutation.
Unfortunately, although many improvements were achieved in cancer biology, for almost all
patients with GBM, life expectancy remains within 18 months [1,2]. Up to now, the combination of
radiotherapy with the oral alkylating agent temozolomide (TMZ) represents the first major advance
in GBM therapy, increasing the mean lifetime survival by 1.8 years [3]. Indeed, the addition of the
anti-vascular endothelial growth factor A antibody, bevacizumab, to standard treatment with TMZ
improves only the progression-free survival but does not affect the overall survival [4]. Notwithstanding
this, the drug was found to be active in patients who did not respond to other standard treatments [5].
A common hallmark of all cancer cells is their ability to migrate and to metastasize other tissues.
Although extracranial metastases are extremely rare, GBM can migrate into the healthy brain tissue,
leading to local or distant cancer dissemination, rendering surgical resection of the tumor impossible
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and conferring to these cells the ability to elude the efficacy of irradiation and chemotherapy [6,7].
Therefore, understanding the molecular mechanisms underlying its aggressive behavior and cell
migration is fundamental in order to develop novel therapeutic strategies to treat GBM patients with
better outcomes.
It was shown that the alteration of glutamate secretion and signaling in GBM and glioma might
play a pivotal role in the invasion and tumor growth [8,9]. In addition, GBM secretes a considerable
amount of glutamate in the microenvironment nearby the cancer, causing excitotoxicity in normal
neurons [10] and increasing expressions of glutamate transporters and glutamine synthetase. This latter
effect might be responsible for the recruitment of tumor-associated microglia/macrophage (TAM),
which mediates tumor cell survival through secretion of IL-10 and Vascular-Endothelial Growth Factor
(VEGF) [11]. Therefore, the glutamate receptor system could be an important target in GBM therapy.
1.1. Oncogenic Pathways in GBM
GBM is a disease where genetic, epigenetic, and post-translational aspects cooperate together in
a complex and well-orchestrated series of events leading to the oncogenic transformations of neuronal
cells. It is commonly accepted that GBMs origin can be ascribed to the so-called stem-cell theory, which
is split into two main hypotheses: the astrocyte dedifferentiation theory and the glioblastoma stem-cell
(GSC) theory. Both are characterized by the presence in astrocytic glioma of a subpopulation of cells
which exhibit neuronal stem-cell-like properties such as multipotentiality, and the ability to self-renew
or to form neurospheres in vitro. Moreover, experiments on a GBM mouse model showed that neural
stem cells and oligodendrocyte precursor cells also have the potential to form glioblastomas, although
with distinct molecular characteristics, reinforcing the stem-cell theory. The important role played
by cytosolic free Ca2+ must also be underlined. Indeed, Ca2+ is involved in a number of signaling
events related to its ability to maintain cell proliferation in tumor cell lines and to commit embryonic
stem cells toward a neuronal phenotype [12]. The most frequently altered pathway in GBM and cancer
in general involves both tyrosine kinase receptors (RTKs) and serine/threonine kinases [13] such as the
epidermal growth factor receptor (EGFR). These receptors bind different growth factors (GFs), and,
upon activation, they dimerize and change their conformation. This event activates the kinase function
of the RTK resulting in downstream signaling cascades. EGFR signaling is involved in several biological
functions such as proliferation, differentiation, survival, and migration of all types of central nervous
system cells [14]. In GBM, the oncogenic properties of EGFR are characterized by an uncontrolled
increase in phosphorylation activity, resulting in uncontrolled cell proliferation. EGF also regulates
the serine/threonine phosphorylation pathways such as the phosphatidylinositol- 4,5-bisphosphate
3-kinase/phosphatase and tensin homolog/serine–threonine kinase Akt (PI3K/PTEN/Akt) which is
implicated in the pathogenesis of GBM [15,16]. In addition, EGFRs and receptor tyrosine kinases
(RTKs) regulate the activities of Ras, an overexpressed oncogene in GBM [17]. Indeed, the Ras/Raf
pathway is modified in GBM. Ras is a guanosine binding protein that becomes active when bound to
Guanosine Triphosphate (GTP). Upon activation, Ras/Raf phosphorylates a series of kinases including
the mitogen-activated protein kinase MAPK family, which in turn regulates downstream target
genes and cell activities. Alterations of the Ras/MAPK pathway are responsible for abnormal cell
growth and proliferation, as well as cell invasion [18]. In addition, it was demonstrated that the
upregulation of Ras/Raf/MAPK and PI3k/Akt/mTOR pathways is a key element promoting TMZ
resistance [19,20], which in turn enables a selection of slow-cycling glioma stem cells (GMCs) able to
escape chemotherapy’s effect [21], originating a chemo-resistant cell subpopulation.
1.2. Glioma Cell Motility and Invasion
The ability of GBM cells to infiltrate the healthy tissue nearby is a crucial point both in disseminating
cancer cells and as a “strategy” to escape from irradiation and chemotherapy. GBM cell infiltration
is a complex and intricated mechanism which is accomplished basically via two main routes, blood
vessels and axons [22]. However, due to such complexity, its biology is still poorly understood;
Int. J. Mol. Sci. 2019, 20, 1796 3 of 13
however, at the same time, it is of great importance for developing novel therapeutic approaches to
treat the disease. The composition of the extracellular matrix (ECM) significantly influences the ability
of glioma cells to migrate. We can assume that the stiffness gradient is one of the major driving forces
of cell motility; therefore, the GBM migrates toward a more rigid micro-environment according to
a durotaxis phenomenon [23]. In addition, it was shown that matrix crosslink-enhanced ECM tension
was able to promote tumor cell migration progression [24,25]. Integrins are catalytic heterodimeric
transmembrane glycoproteins responsible for cell–ECM interactions. Once activated, integrins and the
formation of downstream focal adhesion complexes (FAK) enhance the migration [26] and transduce
mechanical signals into biochemical signals. Among other integrins, β1 seems to play an important
role in cell migration and tumor spreading. In fact, it was shown that β1 integrin protein levels were
strongly and specifically downregulated in cells cultured on soft matrix, causing a decrease in fibrotic
deposition and, possibly, in tumor malignancy [27]. FAKs and integrin β1 are active and overexpressed
in gliomas, and their expression correlates with the tumor grade [28,29]. Interestingly, the finding that
the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subunit GluR1 associates with
integrin β1 suggests that α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors (AMPARs)
might act as membrane-associated cytoskeleton anchors for localized signaling at focal adhesion
complexes [30] and, therefore, might play an important role in GBM cell migration. It should be
underlined also that the cancer microenvironment plays an important role in GBM cell migration.
Indeed, several factors, such as hypoxia [31], deregulated EFGR pathway, and increased intracellular
Ca2+ concentration, are able to activate the migratory machinery in glioma cells [32]. Both ionotropic
and metabotropic glutamate receptors interact with and/or regulate the proteins involved in such
activities, reinforcing the idea that glutamate receptors could be also a key protein target for new
anti-metastatic drugs.
2. Glutamate Receptors and Cancer
In the last decade, considerable evidence describing the involvement of glutamate in tumor
development was reported in both neural and non-neural cancer tissues of both malignant and benign
origin. Both metabotropic [33] and ionotropic [34] glutamate might act as a growth factor and as
a signal mediator in both autocrine and paracrine fashions [35]. The glutamate receptor system is the
main excitatory network of the central nervous system (CNS). It is composed of three sub-families,
two ligand-gated ion channels (ionotropic receptors), the N-methyl-d-aspartate (NMDA) receptors
and the α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)/kainate receptors, and one
metabotropic receptor (mGluR) [36]. The receptor subunit composition of both NMDA and AMPA ion
channels confer specific pharmacological properties to these receptors. Both receptors mediate the
entrance of Na+ and Ca2+ but with different activation kinetics. Indeed, NMDA activity is linked to the
synaptic plasticity involved in learning and memory [37]. The rapid desensitization kinetics of AMPA
receptors mediates the fast excitatory synaptic transmission, which is fundamental in shaping and
driving synaptic plasticity [38]. The rise of intracellular Ca2+ concentration is associated to a number
of Ca2+-dependent signal transduction pathways involved in cell proliferation such as Akt, [39],
ERK/MAP kinase [40], and PKA [41] pathways. Interestingly, GBMs possess the ability to release
glutamate in the nearby environment, which in turn interacts with the specific Ca2+-permeable AMPA
receptor, allowing Ca2+ entrance into the cells and promoting cell migration and proliferation through
Akt activation. The release of glutamate by a transient increase of the intracellular Ca2+ concentration
is also associated with the presence of high levels of ATP in the extracellular matrix, contributing in
part to the influx of external Ca2+ through the ionotropic ATP-gated receptor P2X7 [42]. In addition,
it was shown that the cystine/glutamate antiporter xc(-), which exchanges extracellular cystine for
intracellular glutamate, is upregulated in GBMs [43]. Thus, in the GBM environment, the simultaneous
presence of high levels of ATP and the upregulation of the xc(-) transporter and the expression of
Ca2+-permeable AMPA receptors generate a detrimental scenario that allows GBM to grow and migrate
into brain tissue.
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The increased level of glutamate in the brain also has clinical relevance. Indeed, patients with
GBM showed a concentration of glutamate ranging from 100 to 600 µM, responsible for seizure and
excitotoxicity in cells close to the tumor site [44]. Moreover, it is well known that the microenvironment is
crucial for the regulation of several processes involved in tumor formation and progression, such as the
epithelial–mesenchymal transition, and the maintenance of GSCs by enhancing their self-renewal capacity.
The role of microenvironment also becomes important in the regulation of pH, which, in GBMs, resulted
to be around 6.1, whereas, in normal brain, is around 7.1. This is mainly due to the high metabolic rate of
tumor tissue. This acidic condition contributes to the GBM tumor growth and the self-renewal of GSC [45].
The metabotropic glutamate receptor (mGluR) is a G-protein-coupled receptor localized in both pre- and
post-synaptic regions in CNS. However, mGluRs are not exclusive to the CNS; they are ubiquitously
expressed in different non-neuronal human tissues [46], such as the skin [47], liver, heart [48], and adrenal
gland [49]. Metabotropic glutamate receptors are composed of eight subtypes, mGluR1–8, subdivided
in turn into three groups (group I, II, and III) based on sequence homology and intracellular G-protein
coupling activity [50]. Once activated, they modulate signal transduction through the stimulation of
second messengers such as the phospholipase C/inositol triphosphate/diacylglycerol pathway or by
inhibiting the adenylate cyclase pathway [41,51]. The mGluRs, in the CNS, control the postsynaptic
neuronal response to glutamate, modulating both NMDA and AMPA receptor activity, as well as cellular
proliferation, growth, migration, survival, and calcium-mediated cellular homeostasis [52]. In particular,
group I, characterized by mGluR1 and mGluR5, is coupled to Gαq, which causes stimulation of
Phospholipase C beta (PLCβ) and activation of protein kinase C (PKC), resulting in phosphorylation
of downstream targets. Group II, consisting of mGluR2 and mGluR3, and group III, composed of
mGluR4 and mGluR6–8, are coupled to Gαi/o and, therefore, responsible for the inhibition of adenylyl
cyclase, which potentiates or attenuates different pathways including the mitogen-activated protein
kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/Akt signaling pathways [37,53].
2.1. Metabotropic Glutamate Receptor and GBM
As already mentioned, GBM releases a high amount of glutamate extra-synaptically, thus acting
as a trophic factor, increasing the proliferation and migration of glioma cells. Studies on messenger
RNA (mRNA) expression and protein level amount of mGluR in the GBM cell line and primary culture
from GBM patient resections revealed that group II was the most expressed [54]. Moreover, the finding
by Ciceroni et al. [55] that the low levels of mGluR3 mRNA expression in tumor specimens correlated
with a better survival rate in GBM patients reinforced the idea that the use of an antagonist of mGluR3
might be an important strategy to pursue [54]. In this context, the study of the mGluR2/3 antagonist
LY 341495 on the U87MG glioma cell line showed a dramatic inhibition of cell proliferation, through
a negative regulation of gap 1/synthesis (G1/S) phase transition, without affecting (or involving)
apoptosis [56]. Interestingly, D’Onofrio at al. confirmed these data also on primary cultures from
human GBM; however, in this case, cell growth was restored after washing out LY 341495, indicating
that the antiproliferative effect was cytostatic, rather than cytotoxic [57]. This effect was due to
different molecular mechanisms, involving the ERK1/2 phosphorylation pathway on differentiated
GBM cells and an increase in Smad 1/5/8 phosphorylation, which is a downstream effector of the
morphogenetic protein (BMP), which in turn is relevant in glial cell differentiation of glioblastoma
stem cells (GSC) [58] (Figure 1). Moreover, Yelskaya et al. (2013) suggested a possible synergism
between mGluR2/3 and EGFR, through a common activation of Akt and MAPK pathways, since the
combination of mGluR2/3 antagonist LY 341495 and Iressa, an EGFR inhibitor, is more efficient to inhibit
proliferation and migration and to induce apoptosis in U87MG cells [59]. Recently, Dalley at al. [60]
found a selective mRNA overexpression of mGluR1 in GBM cell lines, suggesting that mGluR1,
when overexpressed, might act as a proto-oncogene by promoting dysregulated proliferation and
survival of glioma cells. To reinforce this idea, the authors evaluated the effect of the noncompetitive
selective mGluR1 antagonist JNJ16259685. The selective antagonist was able to convert Hs683 cells
grown in soft agar from an anchorage-independent phenotype to an anchorage-dependent phenotype,
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indicating that Hs683 cells treated with this antagonist exhibited reduced metastatic and tumorigenic
characteristics in vivo [60]. A molecular explanation for the antitumor effects elicited by antagonists
acting on mGluR1 could reside in the reduction of phosphorylation of PI3K and mTOR target p70
S6K. Indeed, in the U87MG cell line, the inhibition of mGluR1 activity resulted in the inhibition
of Phosphoinositide-3-kinase (PI3K) and Akt/protein kinase B (PKB) phosphorylation, together
with a decreased expression level of phosphorylated (p)-mTOR and P70 S6K, without affecting the
expression of PTEN [61]. As described in the previous section, upregulation of EGFR stimulates survival
signaling through the Ras/Raf/MAPK and PI3K/Akt/mTOR pathways and is involved in GMC TMZ
resistance [20,21] (Figure 1). In this context, Gli-1 protein, a downstream target of Hedgehog signaling
(Hh), might play an important role. In fact, Gli-1 is involved in several cellular functions such as cell
proliferation [62], survival, and migration [63], as well as cancer cell stemness and self-renewal [64],
and its overexpression correlates with malignancy of several cancers including GBM [65]. Interestingly,
Zhang et al. showed that a selective agonist of mGluR3 VU0155041 suppressed cell proliferation of
the glioblastoma cell line LN through the suppression of Gli-1 transcription factor, suggesting this
pathway as a possible key element in the mGluR4 control of GBM cell growth [66], suggesting this
receptor subtype as a potential target for glioblastoma therapy.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 5 of 13 
 
antitumor effects elicited by antagonists cting on mGluR1 could r sid  in the reducti  of 
phosphorylation of PI3K and mTOR ta get p70 S6K. Indeed, in the U87MG cell line, the inhibition of 
mGluR1 activity r sulted in the i hibition of Phosphoinositide-3-kinase (PI3K) and Akt/protei  
kinase B (PKB) phosphorylation, together with a decreased expression level of phosph rylated (p)-
mTOR and P70 S6K, without affecting the expression of PTEN [61]. As described in the previous 
section, upregulation of EGFR stimulates survival signaling through the as/Raf/MAPK and 
PI3K/Akt/mTOR pathw ys nd is involved in GMC TMZ resis ance [20,21] (F gure 1). In this context, 
Gl -1 protein, a downstream target of H dgehog signaling (Hh), might pl y an important role. In fact, 
Gli-1 is involved i  several cellu ar functions such as cell prolif ration [62], survival, and migration 
[63], as well as cancer ce l stemness and self-renewal [64], and its overexpression co relates with 
mal gnancy of s veral ancers including GBM [65]. Interestingly, Zhang et al. showed that a selective 
ago ist of mGluR3 VU0155041 suppressed cell proliferation of the glioblastoma cel  line LN thr ugh 
t  suppre sion of Gli-1 transcription factor, sugge ting this pathway as a possible key element in the 
mGluR4 control of GBM c ll growth [66], suggesting this receptor subtype as a potential target for 
glioblastoma th rapy. 
 
Figure 1. General representation of the signaling pathways involved in the antagonism of both 
ionotropic and metabotropic glutamate receptors in anti-cancer mediated effects. Selective 
metabotropic glutamate receptor 1 (mGluR1) antagonist JNJ1659685 elicited its anti-cancer activity, 
by decreasing cell proliferation, through the inhibition of the phosphoinositide 3-kinase/protein 
kinase B (PI3K/Akt) pathway, and by increasing cell differentiation through the activation of the 
transcription factors small mother against decapentaplegic transcription factor (Smad) 1/5/8. LY 
341495, an mGluR 2/3 selective antagonist, blocks the activation of both the mitogen-activated protein 
kinase (MAPK)/extracellular signal-regulated kinase (ERK)1/2 cascade and the Akt/mammalian 
target of rapamycin protein (mTOR) pathway, resulting in arrest of the cell cycle and an increase in 
apoptosis. Talampanel, a selective negative allosteric α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionic acid (AMPA) modulator, inhibits the rise of intracellular calcium concentration, and 
inhibits both ERK1/2 and Akt phosphorylation, slowing down the cell proliferation, and increasing 
cellular stiffness through the activation of focal adhesion kinase (FAK) protein. The N-methyl-D-
aspartate (NMDA) antagonists, MP1 and MP2, two memantine derivative compounds, exert their 
antiproliferative activity by modulating Beclin-1 binding protein, which increases the autophagic 
processes of glioblastoma cell line. 
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Figure 1. General representation of the signaling path ays involved in the antagonis of both
ionotropic and metabotropic glutamate receptors in anti-cancer mediated effects. Selective metabotropic
glutamate receptor 1 (mGluR1) antagonist JNJ1659685 elicited its anti-cancer activity, by decreasing
cell proliferation, through the inhibition of the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt)
pathway, and by increasing cell differentiation through the activation of the transcription factors small
mother against decapentaplegic transcription factor (Smad) 1/5/8. LY 341495, an mGluR 2/3 selective
antagonist, blocks the activation of both the mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase (ERK)1/2 cascade and the Akt/mammalian target of rapamycin protein (mTOR)
pathway, resulting in arrest of the cell cycle and an increase in apoptosis. Talampanel, a selective
negative allosteric α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, inhibits
the rise of intracellular calcium concentration, and inhibits both ERK1/2 and Akt phosphorylation,
slowing down the cell proliferation, and increasing cellular stiffness through the activation of focal
adhesion kinase (FAK) protein. The N-methyl-d-aspartate (NMDA) antagonists, MP1 and MP2, two
memantine derivative compounds, exert their antiproliferative activity by modulating Beclin-1 binding
protein, which increases the autophagic processes of glioblastoma cell line.
Int. J. Mol. Sci. 2019, 20, 1796 6 of 13
2.2. Glutamate Ion Channels in GBM and Cell Migration
Tumor cell migration is a complex event characterized by highly dynamic and coordinated
biological processes, comprising cell adhesion and detachment, cell motility, and cell invasion.
Adhesion and motility are directly related via the interactions of extracellular matrix (ECM) with
integrins, FAK, and the actomyosin system. Invasion, instead, requires the secretion, by tumor cells,
of proteolytic enzymes such as matrix metalloproteinases (MMPs), able to degrade the surrounding
extracellular matrix. Ionotropic glutamate receptors are cation-specific ion channels which allow
the influx of monovalent ions and also divalent ions such as Ca2+. In GBM, Ca2+ signaling is really
important, since it is involved in a number of functions ranging from the motility of cancer stem
cells to the motility and growth of GBM cells [12]. AMPA receptors are tetrameric ion channel
receptors which can be composed of four different subunits named GluR1, GluR2, GluR3, and GluR4.
In the presence of GluR2, the receptor complex becomes impermeable to Ca2+, and this configuration
is the most widespread in the healthy brain [67]. In GBM, GluR2 is poorly represented, whereas
the AMPA receptor configuration permeable to Ca2+, formed only by GluR1 and GluR4 subunits,
is overexpressed [8,68]. As mentioned above, the overexpression of GluR1 and its correlation with
the high expression of integrin β1 indicate an important role of GluR1 in cell migration and adhesion
in GBM. In addition, Piao et al. showed a direct correlation between the expression of AMPARs
and the level of glioma cell migration, both in vitro and in vivo. This finding is supported also by
the evidence that a high level of GluR1 is associated with high levels of FAKs, and that glutamate
increased Rac1/GTPase activity, an intracellular protein involved in the assembly of integrin adhesion
complex [30] (Figure 1). Moreover, as represented in Figure 1, the important role played by MAPK
and Akt signaling in GBM cell proliferation was proposed to be a downstream event of AMPA
receptor activation through an increase in intracellular Ca2+ [34]. This assumption is supported
also by the finding that GluR2 overexpression inhibits glioblastoma cell proliferation by inactivating
MAPK and inducing apoptosis of tumor cells [69]. Further evidence comes from the fact that GluR1
knock-down inhibits AMPAR-mediated activation of the MAPK pathway and decreases glioma cells
proliferation [70]. As already discussed, it is well known that the tumor microenvironment plays
a crucial role in the survival and propagation of cancer cells [71]. Both Ca2+ and EGFRs are key elements
in this environment, upregulating the plasma membrane antiporter xc(-), which are essential for the
exchange of extracellular cysteine and intracellular glutamate [32] and enhancing the hypoxia-inducible
factor (HIF) activity, respectively [72], thus promoting, partially through AMPAR, tumor cell migration.
EGFRs, whose expression is deregulated in GBM, were shown to interact also with NMDA receptors,
and in particular with the NR2B subunit [73]. NMDA receptors are heterotetrameric ion channels
composed of different subunits: GluN1, a glycine/d-serine binding subunit, and GluN2 (GluN2A-D)
or GluN3 (GluN3A-B), a glutamate-binding subunit [74]. The phosphorylation of NR2B by EGFR
increases the intracellular Ca2+ concentration and, therefore, tumor growth and spreading. Recently,
Wan-Soo et al. reported the effect of memantine, a GluN1 antagonist, on a glioblastoma cell line.
Interestingly, the drug, which is used in Alzheimer’s and Parkinson’s diseases, was able to reduce
cell proliferation and increase autophagy in the T-98G cell line. These effects were mediated by the
interaction with GluN1, by increasing the expression of Beclin-1, which in turn regulates the autophagic
pathway. [75]. Moreover, novel memantine-derived drugs, called MP1 and MP2, were found to
inhibit cell proliferation and increase apoptosis in the U87MG glioblastoma cell line, without affecting
significantly the cell viability of primary human whole blood cells [76].
2.3. Glutamate Receptor and Biomechanic Features of GBM
As mentioned in previous sections, it was demonstrated that tumor microenvironment affects
cancer cells properties including proliferation, death, and motility [71]. Several studies in the last
decades revealed how living cell behavior can also be affected by mechanical and other biophysical cues
from the cell microenvironment [77,78] giving rise to a dynamic and reciprocal exchange of mechanical
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and biochemical information. These mechanical signals play a key role in a global comprehension of
disease processes as they may contribute to the pathogenesis and/or be used as a target for therapeutics.
Focusing specifically on GBM, it was demonstrated that invasive properties of tumor cells can be
regulated by ECM stiffness, which provides an active and dynamic microenvironmental cue able to
mediate the contractile actomyosin bundles [79]. In particular, it was proposed that GBM cells may
induce a stiffening of microenvironmental properties during growth and spreading and that these
remodeling phenomena can give rise to a reciprocal mechanical signaling exchange with those cells
that promote tumor invasion (Figure 2). Investigations about the role of ECM-based substrates with
different stiffness on GBM behavior led Ulrich et al. [24] to assert, for the first time, a remarkable
stiffness-dependent behavior in glioma cell migration and proliferation. These findings assume
an outstanding relevance when considering the different mechanical microenvironmental features
associated with healthy and tumor brain tissue. In fact, it is generally recognized that GBM tumors
and their surrounding stroma are stiffer if compared with healthy brain tissue. Interestingly, they also
demonstrated the feasibility to bypass their dependence on stiffness by pharmacologically inhibiting
the actin motor protein non-muscle myosin II (NMMII). These interesting results highlight the key
role of both mechanical signals present in the tumor microenvironment and the molecular complexes
which are able to sense and process these signals, opening new perspectives for understanding and
manipulating glioma cell physiology, as well as for therapeutics.
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 7 of 13 
 
Focusing specifically on GB , it was demonstrated that invasive properties of tumor cells can 
be regulated by ECM stiffness, which provides an active and dynamic microenvironmental cue able 
to mediate the contractile actomyosin bundles [79]. In particular, it was proposed that GB  cells may 
induce a stiffening of microenvironmental properties during growth and spreading and that these 
remodeling phenomena can give rise to a reciprocal mechanical signaling exchange with those cells 
that promote tumor invasion (Figure 2). Investigations about the role of EC -based substrates with 
different stiffness on GB  behavior led Ulrich et al. [24] to assert, for the first time, a remarkable 
stiffness-dependent behavior in glioma cell migration and proliferation. These findings assume an 
outstanding relevance when considering the different mechanical microenvironmental features 
associated with healthy and tu or brain tissue. In fact, it is generally recognized that GB  tu ors 
and their surrounding stro a are stiffer if compared with healthy brain tissue. Interestingly, they 
also demonstrated the feasibility to bypass their dependence on stiffness by pharmacologically 
inhibiting the actin motor protein non-muscle myosin II (NMMII). These interesting results highlight 
the key role of both mechanical signals present in the tumor microenvironment and the molecular 
complexes which are able to sense and process these signals, opening new perspectives for 
understanding and manipulating glioma cell physiology, as well as for therapeutics. 
 
Figure 2. Schematic representation of cell reorganization on soft and rigid extracellular matrix (ECM) 
substrates. The actomyosin II system connected to focal adhesion complexes generates intracellular 
contractile forces which are transmitted to the underlying substrate, following a dynamic and mutual 
information exchange that can lead to changes in cell motility. A soft substrate (left) entails reduced 
activation of integrins, not allowing the formation of stress fibers within the cell. Conversely (right), 
a rigid substrate promotes the integrin activation, as well as a remarkable recruitment of actin 
filaments, leading to a global reinforcement of the cell, thus affecting the cell migration ability. 
Umesh et al. went further, revealing that the microenvironmental rigidity dependency of GBM 
tumor cell behavior occurs via the alteration of EGFR-dependent signaling [80]; in particular, it was 
demonstrated that an enhanced environmental stiffness modulates expression and phosphorylation 
of EGFR and its downstream effector Akt, also affecting a wide range of other signals along the EGFR 
pathway involved in proliferation. Moreover, they found that rigid substrates not only affect GBM 
cell proliferation but also promote the passage through the G1/S checkpoint of the cell cycle, 
consistent with an EGFR-dependent process [81]. They finally revealed how the pharmacological 
inhibition of EGFR, Akt, or PI3 kinase pathways results in a significantly less stiffness-dependent 
proliferation, confirming that mechanical cues such as ECM substrate stiffening promotes GBM 
proliferation by acting on EGFR signaling pathways. 
As highlighted in previous sections, even if the overall mechanism remains not completely clear, 
it is understood that an over-activation of glutamate receptors is associated with neurodegenerative 
disease processes. In particular, it was found that there is a strong correlation between the NMDA 
receptor degeneration and the dynamic remodeling of a wide range of intracellular Rho GTPases, 
including Rac, Rho, and Cdc42, and other actin-binding proteins [82]. In this context, studies about 
mechanical changes of neuroblastoma cells connected with glutamate-mediated neurodegeneration 
were recently performed [83]. In 2013, Zou et al. evaluated, using atomic force microscopy (AFM)-
based measurements, a huge increase in the Young’s modulus of cortical neurons exposed to NMDA, 
Figure 2. Schematic representation of ce l reorganization on soft and rigid extrace lular matrix (ECM)
substrates. The actomyosin I system connected to focal adhesion co plexes generates intrace lular
contractile forces hich are trans i ted to the underlying substrate, fo lo ing a dyna ic and mutual
information exchange that can lead to changes in ce l otility. A soft substrate (left) entails reduced
activation of i te ri s, f stress fibers within the cell. Conversely (right), a
rigid substrate prom tes the integrin activ tion, as well as a remarkable recruitment of acti filaments,
le ding to a global reinf rcem nt f the cell, thus affecting the cell migration ability.
U esh et al. went further, revealing that the icroenviron ental rigidity dependency of GB
tu or cell behavior occurs via the alteration of EGFR-dependent signaling [80]; in particular, it was
demonstrated that an enhanced environmental stiffness modulates expression and phosphorylation of
EGFR and its downstream effector Akt, also affecting a wide range of other signals along the EGFR
pathway involved in proliferation. oreover, they found that rigid substrates not only affect GBM cell
proliferation but also promote the passage through the G1/S checkpoint of the cell cycle, consistent
with an EGFR-dependent process [81]. They finally revealed how the pharmacological inhibition of
EGFR, Akt, or PI3 kinase pathways results in a significantly less stiffness-dependent proliferation,
confirming that mechanical cues such as ECM substrate stiffening promotes GBM proliferation by
acting on EGFR signaling pathways.
As highlighted in previous sections, even if the overall mechanism remains not completely clear,
it is understood that an over-activation of gluta ate receptors is associated ith neurodegenerative
disease processes. In particular, it was found that there is a strong correlation bet een the DA
receptor degeneration and the dynamic remodeling of a wide range of intracellular Rho GTPases,
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including Rac, Rho, and Cdc42, and other actin-binding proteins [82]. In this context, studies about
mechanical changes of neuroblastoma cells connected with glutamate-mediated neurodegeneration
were recently performed [83]. In 2013, Zou et al. evaluated, using atomic force microscopy (AFM)-based
measurements, a huge increase in the Young’s modulus of cortical neurons exposed to NMDA, which
was correlated to high hydrostatic pressure inside the neurons [84]. More recently, Fang and coauthors
focused their attention on dynamic actin filament reorganization of neuroblastoma cells as a consequence
of NMDA exposure; they showed a direct link between NMDA treatment and cell mechanical property
changes, including an enhanced level of surface roughness and higher stiffness [83]. These findings,
coupled with the mechanical approach, allow dynamic monitoring of changes occurring at the
single-cell level, providing not only information about the neurodegenerative mechanism at the basis
of several pathological processes but also an innovative diagnostic tool useful for drug screening and
to develop new therapeutic agents.
3. Future Perspective
All these important findings strongly highlight the possibility to candidate both ionotropic and
metabotropic glutamate receptors as pharmacological targets in GBM treatment. However, up to
now, the only drugs that reached the phase I or II of clinical trials are the selective AMPA antagonist
talampanel and the NMDA antagonist memantine. In particular, talampanel was found to increase
the median survival of patients with GBM (20.3 months versus 14.6 months) in a cohort study of 60
patients [85]. However, the clinical use of talampanel in GBM did not reach the final phase of clinical
trials and is not in the guidelines for the treatment of GBM, either alone or in association with other
therapies. Memantine was proposed for the treatment of GBM in phase I clinical trial (NCT01260467),
in a repurposing drug strategy for recurring GBM. Unfortunately, due to the poor number of patients
enrolled or to the poor patient accrual, there are no available results. However, another phase I clinical
trial is still ongoing, aimed at evaluating the anticancer activity of memantine associated with TMZ
(NCT01430351). As described previously, the acidic microenvironment plays an important role in
both GSC maintenance and GBM growth. Recently, the ability of new series of allosteric NMDAR
inhibitors was reported, which showed greater potency in acidic conditions [86]. Although these
inhibitors were designed primarily for traumatic brain injuries or stroke, the acidic feature of the GBM
microenvironment could be exploited to target new drugs, acting on glutamate receptors, selective
only for GBM. Despite the encouraging results obtained involving the glutamatergic system in glioma
and GBM biology, the number of clinical trials on these types of cancer is really low. The reasons for the
lack of clinical trials, in addition to the difficulty of transferring the preclinical test to the clinical one,
such as the controlled environment of cultured cells, could be ascribed to two main points. The first
one might reside in the possible unwanted side effects elicited by specific antagonists on this system,
such as loss of memory, mood alteration, ataxia, and hallucination, in particular when using ligands
acting on ionotropic receptors. The second one, regarding the metabotropic receptors, relies mainly on
the needs of further research, aimed at better understanding the activity and the molecular mechanism
of specific positive or negative allosteric ligands acting on mGluRs, in parallel to the investigation of
their safety and tolerability profile. However, it must be underlined that, from a pharmacological
point of view, the evaluation of the degree of risk and benefit and the therapeutic window should be
carefully taken into account, especially if we consider the poor prognosis and lethality of GBM.
Finally, the evidence that the positive allosteric modulation of metabotropic glutamate receptors
mGlu1 and mGlu4 was shown to be neuroprotective, whereas the negative allosteric modulation,
acting on mGlu3, was able to interfere with cell proliferation, differentiation, and chemoresistance [87]
strongly suggests the mGluRs as promising targets, and reinforces the idea of a possible use, in the
future, of new specific ligands acting on the glutamatergic receptor system, alone or in combination
with other drugs, in the treatments of GBM. Moreover, the ability of NMDA receptors to modulate
the mechanical properties of the tumor cells highlights the possibility to have more tools to study the
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dynamic features of tumor cells within their microenvironments and, therefore, to better understand the
cancer biology both for a diagnostic purpose and to develop new anticancer strategies and/or agents.
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